Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
The selective estrogen-receptor degrader imlunestrant plus abemaciclib led to a median progression-free survival of 9.4 months among patients with ER-positive, HER2-negative breast cancer (vs....
Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A
New England Journal of Medicine, Ahead of Print.
massmed: New England Journal of Medicine: Table of Contents
Liberal or Restrictive Transfusion Strategy in Aneurysmal Subarachnoid Hemorrhage
New England Journal of Medicine, Ahead of Print.
massmed: New England Journal of Medicine: Table of Contents
Long-Acting HIV Medicines and the Pandemic Inequality Cycle — Rethinking Access
New England Journal of Medicine, Ahead of Print.
massmed: New England Journal of Medicine: Table of Contents
Could Lentivirus Overcome the AAV Gene-Therapy Challenges in Hemophilia A?
New England Journal of Medicine, Ahead of Print.
massmed: New England Journal of Medicine: Table of Contents
